TDMS Study 96020-01 Pathology Tables
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:12:20
FINAL #1
Facility: Battelle Columbus Laboratory
Chemical CAS #: TEFBINARYMIX
Lock Date: 03/27/02
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include 001 0 NG / 0 UG
Include 004 300 NG /100 UG
Include 005 300 NG /300 UG
Include 006 300 NG /3000 UG
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 1
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:12:20
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 300 NG / 300 NG / 300 NG /
0 UG 100 UG 300 UG 3000 UG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 98 80 98 80
Early Deaths
Moribund Sacrifice 22 10 19 13
Natural Death 8 12 10 10
Dosing Accident 1 1
Survivors
Terminal Sacrifice 22 28 24 27
Animals Examined Microscopically 53 50 53 51
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (53) (50) (53) (50)
Perforation 1 [3.0]
Muscularis, Inflammation 3 [1.3] 3 [1.3]
Periesophageal Tissue, Hemorrhage 1 [2.0]
Periesophageal Tissue, Inflammation 1 [3.0] 1 [3.0]
Intestine Large, Rectum (53) (50) (53) (51)
Parasite Metazoan 2 1 1 2
Artery, Inflammation, Chronic Active 1 [2.0] 2 [2.5]
Intestine Large, Cecum (53) (50) (52) (50)
Edema 1 [2.0]
Inflammation 1 [2.0]
Artery, Inflammation 1 [2.0]
Artery, Inflammation, Chronic Active 1 [2.0]
Artery, Thrombosis 1 [3.0]
Lymphoid Tissue, Hyperplasia 1 [3.0]
Intestine Small, Jejunum (53) (50) (52) (51)
Hyperplasia, Lymphoid 2 [3.5]
Ulcer 1 [4.0]
Intestine Small, Ileum (53) (50) (52) (50)
Hyperplasia, Lymphoid 1 [2.0]
Liver (53) (50) (52) (51)
Angiectasis 3 [1.7] 1 [2.0] 2 [2.0] 3 [2.0]
Basophilic Focus 9 4 2 8
Basophilic Focus, Multiple 13 1 1 10
Cholangiofibrosis 5 [2.4] 7 [2.0] 13 [2.2]
Clear Cell Focus 3 1 3 5
Clear Cell Focus, Multiple 6 4 6
Eosinophilic Focus 7 6 7
Eosinophilic Focus, Multiple 7 21 33 45
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 2
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:12:20
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 300 NG / 300 NG / 300 NG /
0 UG 100 UG 300 UG 3000 UG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Fatty Change, Diffuse 3 [1.7] 28 [1.1] 31 [1.5] 47 [1.5]
Fatty Change, Focal 3 [1.0] 4 [1.3] 1 [2.0] 11 [1.9]
Hematopoietic Cell Proliferation 27 [1.2] 18 [1.1] 19 [1.1] 29 [1.1]
Hemorrhage 1 [3.0]
Hyperplasia, Nodular 20 24 21
Inflammation 44 [1.1] 47 [1.2] 48 [1.2] 46 [1.2]
Mixed Cell Focus 7 2 1
Mixed Cell Focus, Multiple 19 27 24 26
Necrosis 4 [1.8] 6 [2.5] 4 [1.0] 7 [2.1]
Pigmentation 2 [1.0] 50 [1.9] 50 [1.9] 44 [1.8]
Toxic Hepatopathy 44 [1.6] 48 [2.0] 48 [2.8]
Bile Duct, Cyst 4 [2.3] 4 [1.8] 5 [2.4] 6 [2.5]
Bile Duct, Fibrosis 1 [1.0] 4 [1.0] 5 [1.6]
Bile Duct, Hyperplasia 8 [1.3] 20 [1.2] 29 [1.4] 40 [1.7]
Centrilobular, Degeneration 5 [1.8] 6 [2.5] 4 [1.5] 2 [3.0]
Centrilobular, Fibrosis 1 [2.0] 1 [1.0]
Hepatocyte, Hypertrophy 1 [1.0] 22 [2.1] 33 [2.1] 47 [3.0]
Hepatocyte, Multinucleated 42 [1.4] 46 [1.6] 44 [1.5]
Oval Cell, Hyperplasia 2 [1.0] 33 [1.3] 39 [1.6] 43 [2.1]
Portal, Fibrosis 3 [1.3] 7 [1.4] 10 [1.6]
Serosa, Inflammation, Chronic Active 1 [3.0]
Mesentery (47) (31) (47) (47)
Artery, Inflammation, Chronic Active 1 [1.0] 1 [3.0] 2 [2.5] 1 [3.0]
Fat, Necrosis 1 [3.0]
Oral Mucosa (12) (28) (30) (41)
Gingival, Hyperplasia, Squamous 8 [1.3] 21 [1.6] 22 [1.6] 29 [1.5]
Pancreas (53) (49) (52) (49)
Inflammation, Chronic Active 5 [1.2] 1 [1.0] 5 [1.8]
Necrosis 1 [1.0]
Acinus, Atrophy 4 [1.8] 1 [1.0] 5 [2.0]
Acinus, Hyperplasia 2 [1.5] 1 [3.0] 1 [2.0]
Acinus, Vacuolization Cytoplasmic 3 [1.0] 7 [1.0] 44 [1.5]
Artery, Inflammation, Chronic Active 4 [2.0] 2 [2.5] 3 [1.7]
Stomach, Forestomach (53) (50) (52) (51)
Cyst 1 [2.0]
Hyperkeratosis 2 [2.0] 2 [2.0]
Hyperplasia, Squamous 1 [2.0] 6 [2.0] 7 [2.0] 9 [2.0]
Inflammation 1 [2.0] 6 [1.8]
Mineralization 1 [1.0]
Ulcer 1 [1.0] 2 [2.5] 1 [2.0]
Artery, Inflammation, Chronic Active 2 [2.0]
Stomach, Glandular (53) (50) (52) (51)
Ectopic Tissue 1 [4.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 3
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:12:20
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 300 NG / 300 NG / 300 NG /
0 UG 100 UG 300 UG 3000 UG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Erosion 3 [2.0] 1 [2.0]
Mineralization 4 [1.5] 1 [1.0] 1 [2.0]
Tooth (23) (25) (35) (42)
Peridontal Tissue, Inflammation 23 [1.2] 25 [1.3] 35 [1.5] 42 [1.4]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (53) (50) (53) (51)
Aorta, Mineralization 1 [3.0]
Heart (53) (50) (53) (50)
Cardiomyopathy 22 [1.0] 18 [1.1] 26 [1.1] 25 [1.0]
Inflammation, Chronic Active 1 [4.0]
Mineralization 1 [2.0]
Thrombosis 1 [3.0]
Coronary Artery, Inflammation, Chronic Active 1 [2.0]
Endocardium, Hyperplasia 1 [1.0]
Pericardium, Necrosis 1 [3.0]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (53) (49) (52) (51)
Angiectasis 17 [1.4] 28 [1.6] 23 [1.7] 7 [1.9]
Atrophy 2 [3.0] 3 [3.0] 5 [2.4]
Degeneration, Cystic 13 [2.1] 14 [2.2] 14 [1.8] 18 [2.0]
Hematopoietic Cell Proliferation 1 [1.0]
Hyperplasia 11 [2.2] 17 [2.5] 25 [2.6] 21 [2.8]
Hypertrophy 47 [2.0] 42 [2.2] 41 [2.3] 40 [1.9]
Necrosis 1 [3.0] 3 [2.3] 2 [2.0]
Vacuolization Cytoplasmic 11 [1.5] 15 [1.5] 10 [1.4] 13 [1.6]
Adrenal Medulla (52) (49) (52) (49)
Hyperplasia 15 [1.8] 8 [1.5] 13 [2.1] 6 [1.5]
Islets, Pancreatic (53) (49) (52) (49)
Hyperplasia 1 [2.0]
Pituitary Gland (53) (50) (52) (51)
Angiectasis 17 [2.4] 14 [2.4] 17 [2.0] 7 [2.0]
Cyst 1 [2.0]
Cytoplasmic Alteration 1 [2.0] 2 [2.5]
Inflammation 1 [2.0]
Necrosis 1 [2.0]
Vacuolization Cytoplasmic 1 [2.0] 2 [1.5]
Pars Distalis, Hyperplasia 13 [2.4] 17 [2.2] 20 [2.5] 21 [2.2]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 4
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:12:20
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 300 NG / 300 NG / 300 NG /
0 UG 100 UG 300 UG 3000 UG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Thyroid Gland (53) (49) (52) (50)
Fibrosis 1 [2.0]
Inflammation, Chronic 1 [3.0]
C-Cell, Hyperplasia 15 [2.1] 16 [1.8] 12 [2.3] 17 [1.8]
Follicle, Cyst 2 [2.0]
Follicular Cell, Hyperplasia 1 [4.0]
Follicular Cell, Hypertrophy 14 [1.3] 28 [1.6] 35 [1.5] 44 [1.8]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (53) (49) (53) (50)
Hyperplasia, Squamous 1 [2.0]
Inflammation 45 [1.8] 38 [1.4] 40 [1.4] 40 [1.2]
Duct, Cyst 38 [2.1] 41 [2.5] 43 [2.3] 41 [2.3]
Ovary (53) (48) (52) (50)
Atrophy 45 [4.0] 46 [4.0] 43 [4.0] 36 [3.9]
Cyst 14 [2.4] 16 [2.0] 14 [2.6] 19 [2.3]
Inflammation, Chronic Active 1 [2.0] 4 [2.8]
Inflammation, Granulomatous 1 [3.0]
Inflammation, Suppurative 1 [2.0]
Oviduct (1) (1) (2) (3)
Cyst 1 [2.0] 2 [2.0]
Inflammation, Chronic Active 3 [3.0]
Metaplasia, Squamous 1 [4.0]
Uterus (53) (50) (52) (50)
Adenomyosis 1 [2.0]
Hemorrhage 1 [3.0]
Inflammation, Chronic Active 3 [2.3] 4 [2.5] 7 [2.6] 8 [3.0]
Inflammation, Suppurative 3 [1.3] 2 [2.0] 10 [1.6] 8 [1.5]
Metaplasia, Squamous 27 [2.0] 27 [2.7] 36 [2.9] 34 [2.8]
Cervix, Cyst 1 [3.0]
Endometrium, Hyperplasia, Cystic 28 [2.0] 25 [2.5] 18 [2.2] 15 [2.3]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (50) (53) (51)
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 5
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:12:20
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 300 NG / 300 NG / 300 NG /
0 UG 100 UG 300 UG 3000 UG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Hyperplasia 39 [3.2] 38 [2.6] 48 [2.8] 39 [3.1]
Lymph Node (4) (2) (7) (5)
Angiectasis 1 [2.0]
Inguinal, Hyperplasia, Plasma Cell 1 [2.0]
Lumbar, Ectasia 4 [2.3] 1 [2.0] 1 [3.0]
Lumbar, Hemorrhage 1 [2.0]
Lumbar, Hyperplasia, Plasma Cell 4 [2.3]
Mediastinal, Ectasia 2 [2.5]
Mediastinal, Hemorrhage 1 [2.0] 2 [2.0]
Mediastinal, Hyperplasia, Histiocytic 1 [2.0] 1 [2.0]
Mediastinal, Hyperplasia, Lymphoid 1 [4.0]
Mediastinal, Hyperplasia, Plasma Cell 1 [2.0] 1 [2.0]
Pancreatic, Hyperplasia, Histiocytic 1 [2.0]
Pancreatic, Pigmentation 1 [2.0]
Renal, Ectasia 1 [2.0]
Renal, Hyperplasia, Histiocytic 1 [2.0]
Renal, Hyperplasia, Plasma Cell 1 [2.0]
Lymph Node, Mandibular (53) (49) (50) (49)
Congestion 1 [3.0]
Ectasia 3 [1.7] 2 [2.0]
Hyperplasia, Lymphoid 1 [2.0] 2 [2.0] 2 [3.0]
Hyperplasia, Plasma Cell 37 [2.2] 33 [2.3] 36 [2.4] 32 [2.4]
Lymph Node, Mesenteric (53) (49) (52) (49)
Hemorrhage 1 [2.0]
Hyperplasia, Histiocytic 1 [2.0]
Hyperplasia, Lymphoid 1 [4.0]
Hyperplasia, Plasma Cell 1 [2.0] 2 [2.0]
Spleen (53) (49) (52) (49)
Fibrosis 1 [3.0]
Hematopoietic Cell Proliferation 51 [2.2] 41 [2.0] 47 [2.0] 45 [2.0]
Pigmentation 47 [1.5] 48 [1.8] 51 [1.7] 49 [1.6]
Lymphoid Follicle, Atrophy 5 [2.6] 4 [2.5] 2 [2.5]
Red Pulp, Atrophy 1 [2.0] 1 [3.0] 1 [2.0]
Thymus (53) (48) (50) (47)
Atrophy 33 [2.3] 48 [3.5] 42 [3.8] 45 [3.4]
Cyst 1 [3.0]
Hemorrhage 1 [2.0] 3 [2.3]
Hyperplasia, Lymphoid 2 [2.5]
Epithelial Cell, Hyperplasia 1 [2.0]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 6
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:12:20
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 300 NG / 300 NG / 300 NG /
0 UG 100 UG 300 UG 3000 UG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - CONT
Mammary Gland (53) (50) (53) (51)
Cyst 3 [3.0] 2 [2.0] 3 [2.3] 2 [2.5]
Hyperplasia 29 [1.5] 14 [1.6] 22 [1.4] 15 [1.5]
Inflammation, Granulomatous 5 [2.0] 2 [2.0] 3 [1.7]
Duct, Cyst 1 [4.0]
Skin (53) (50) (53) (51)
Angiectasis 1 [3.0]
Cyst Epithelial Inclusion 1
Edema 1 [3.0]
Fibrosis 1 [3.0]
Inflammation 2 [3.0]
Necrosis 1 [3.0]
Subcutaneous Tissue, Edema 1 [3.0]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1) (1) (3)
Inflammation 1 [3.0]
Necrosis 1 [3.0]
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (50) (52) (51)
Hemorrhage 1 [2.0] 1 [3.0]
Hydrocephalus 1 [2.0] 1 [2.0] 1 [2.0]
Cerebellum, Hemorrhage 1 [2.0]
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (53) (50) (53) (50)
Hemorrhage 1 [1.0]
Infiltration Cellular, Histiocyte 47 [1.8] 49 [1.8] 46 [1.7] 40 [1.4]
Inflammation 8 [1.8] 2 [1.5] 4 [1.8] 2 [1.0]
Metaplasia, Squamous 3 [2.7] 2 [1.5] 6 [1.7]
Mineralization 1 [2.0]
Alveolar Epithelium, Hyperplasia 23 [1.2] 5 [1.2] 5 [1.4] 8 [1.3]
Alveolar Epithelium, Metaplasia, Bronchiolar 39 [1.7] 34 [1.7] 30 [1.8]
Mediastinum, Necrosis 1 [2.0] 1 [3.0]
Serosa, Inflammation 1 [2.0]
Nose (53) (50) (53) (51)
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 7
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:12:20
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 300 NG / 300 NG / 300 NG /
0 UG 100 UG 300 UG 3000 UG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Hyperplasia 1 [3.0]
Inflammation 22 [1.5] 17 [1.2] 13 [1.6] 15 [1.7]
Nerve, Degeneration 1 [3.0]
Olfactory Epithelium, Degeneration 1 [2.0] 1 [2.0]
Olfactory Epithelium, Dysplasia 1 [3.0]
Olfactory Epithelium, Metaplasia 4 [2.3] 5 [2.0] 6 [2.2] 5 [2.0]
Respiratory Epithelium, Hyperplasia 10 [2.4] 14 [2.1] 11 [2.1] 12 [2.3]
Respiratory Epithelium, Metaplasia 1 [2.0]
Trachea (53) (50) (53) (50)
Inflammation 1 [1.0]
Peritracheal Tissue, Inflammation 1 [3.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (53) (50) (52) (51)
Anterior Chamber, Ciliary Body, Cornea,
Inflammation 2 [3.0] 1 [3.0]
Cornea, Inflammation 1 [1.0] 1 [3.0]
Retina, Atrophy 1 [2.0] 2 [2.0] 5 [2.0]
Harderian Gland (53) (49) (52) (51)
Inflammation 20 [1.0] 15 [1.2] 14 [1.3] 17 [1.1]
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (53) (48) (52) (51)
Accumulation, Hyaline Droplet 2 [2.0] 1 [2.0] 2 [1.5]
Calculus Micro Observation Only 7 6 4 6
Casts Protein 2 [2.0]
Cyst 1 [2.0] 1 [3.0]
Hydronephrosis 2 [3.0]
Infarct 2 [2.5]
Inflammation, Chronic Active 1 [2.0] 1 [3.0] 1 [1.0]
Inflammation, Suppurative 5 [1.2] 6 [1.8] 5 [1.0] 3 [1.0]
Mineralization 42 [1.0] 39 [1.1] 42 [1.0] 33 [1.0]
Nephropathy 29 [1.2] 30 [1.2] 34 [1.3] 34 [1.5]
Pigmentation 2 [1.5] 7 [1.3] 17 [1.5]
Pelvis, Dilatation 1 [2.0] 4 [2.0] 2 [2.5]
Pelvis, Inflammation 3 [2.0] 1 [2.0] 3 [2.3] 8 [2.3]
Renal Tubule, Degeneration 2 [2.0]
Renal Tubule, Hyperplasia 1 [2.0]
Transitional Epithelium, Hyperplasia 2 [2.0] 6 [2.2] 11 [1.9] 9 [2.8]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 8
NTP Experiment-Test: 96020-01 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 03/03/04
Route: GAVAGE TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153) Time: 10:12:20
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG / 300 NG / 300 NG / 300 NG /
0 UG 100 UG 300 UG 3000 UG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Ureter (1) (1) (1)
Inflammation 1 [2.0] 1 [2.0] 1 [2.0]
Transitional Epithelium, Hyperplasia 1 [3.0] 1 [3.0]
Urinary Bladder (53) (49) (52) (50)
Inflammation 7 [1.1] 3 [1.0] 7 [1.4] 8 [1.4]
Transitional Epithelium, Hyperplasia 1 [2.0] 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 9
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------